Company intelligence / Profile preview

Zai Biopharmaceutical

Shanghai, Shanghai, Chinair.zailaboratory.com ↗

Ownership: Private
Employees: ~2100
Development stage: Other

Overview

Zai Lab is a leading China/US-based biopharma with a broad late-stage and commercial portfolio focused on oncology, immunology/autoimmune disorders, neuroscience, and infectious diseases. It has launched five drugs in China—including ZEJULA (niraparib), VYVGART (efgartigimod alfa injection), repotrectinib—and maintains an extensive clinical development pipeline through both internal R&D and global partnerships.

Therapeutic areas: Infectious DiseasesImmunologyOncology
Modalities: Small moleculeMonoclonal antibodyAntibody-drug conjugateFc fragmentBispecific monoclonal antibody (BiTE)
Industry: Biotech

Partnerships

AmgenMirati TherapeuticsSeagenBiogenIpsenTakedaMediLinkNovartis PharmaceuticalsRegeneron PharmaceuticalsNovocureBristol Myers Squibb

Beyond the preview

Go deeper on Zai Biopharmaceutical.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Zai Biopharmaceutical.

Explore the full profile